Stem Cell Clinic

Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS

By adminJanuary 8, 2024Global News Feed

BOSTON, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS).

See the original post:
Dewpoint Therapeutics Filed Multiple Patent Applications with the US Patent Office on Novel Composition of Matter for the Treatment of ALS

Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

By adminJanuary 8, 2024Global News Feed

2023 Total Revenue of ~$399.4M, a 21% Increase Year-Over-Year

Go here to read the rest:
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook

Ascendis Pharma Introduces Vision 2030

By adminJanuary 8, 2024Global News Feed

COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference.

Read more from the original source:
Ascendis Pharma Introduces Vision 2030

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and…

By adminJanuary 8, 2024Global News Feed

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S.

Here is the original post:
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and...